Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

Pediatric Patients with Atopic Dermatitis Have Lower SCH and Higher TEWL, Compared to Those Without

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Researchers found the combination therapy significantly reduced rosacea severity, with 64% achieving mild or normal status in just 4 weeks.

IPL and BoNT/A Synergy for Rosacea 

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Optimizing Care for Patients with Urticaria

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Cytrellis' new president and CEO discusses bridging surgery and innovation in aesthetics.

Denise Dajles, DEng, MSc, Ushers in a New Era at Cytrellis Biosystems, Looks to Future of Aesthetics Industry

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward. 

New Long-Term KEYNOTE-716 Data Presented at ASCO 2023 

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

 are taking the opportunity to reassess and refocus our content to better serve our readers. We value your perspective and want to make sure that the topics and formats we provide continue to meet your professional needs and interests. 

To help guide us in the right direction, we’re asking you to participate in a brief poll that will give us insight into what you’re most interested in seeing more of on our website.

This is more than just a one-time request; it’s part of an ongoing effort to ensure we stay aligned with what’s important to you. Whether it’s updates on the latest dermatology research, insights into clinical practices, or coverage of industry trends, your feedback will help shape our content in the months ahead. 

We want to know what topics matter most to you and how we can make our coverage more valuable for your work. We’ll use the results to prioritize content that speaks to the needs and interests of our readership, making sure our resources are relevant and timely. 

 community and helping us create the most meaningful and impactful content possible in the new year.

Advanced practice provider/NP/PA resources and insights

Want to share more of your insights and perspectives with us? Email our team at

Dermatology Times is reassessing its content strategy for 2025 to better align with readers' professional needs. They are conducting a poll to gather insights on preferred topics and formats, emphasizing the importance of ongoing reader feedback. The goal is to prioritize content that is relevant, timely, and valuable, covering areas such as dermatology research, clinical practices, and industry trends. Reader participation is crucial in shaping future content, ensuring it remains meaningful and impactful for the dermatology community.

Share your thoughts and help shape our content by telling us what topics you want to see more of this year.

Polls 

POLL: What Topics and Content Would You Like to See More of From Us?

The upcoming year is poised to bring significant advancements in dermatologic treatments, with 3 highly anticipated Prescription Drug User Fee Act (PDUFA) dates on the horizon. These therapies address pressing unmet needs in dermatology and promise to enhance patient care.

First, dupilumab (Dupixent) has the potential to become the first targeted therapy for chronic spontaneous urticaria in over a decade. Backed by strong data from the LIBERTY-CUPID clinical trials, Dupixent offers hope for patients struggling with uncontrolled itching and hives.

Next, prademagenezamikeracel (pz-cel) may revolutionize care for patients with recessive dystrophic epidermolysis bullosa, a rare and debilitating condition. The FDA's acceptance of Abeona Therapeutics’ resubmitted Biologics License Application puts this innovative gene therapy one step closer to addressing unmet needs in wound healing and pain management.

Finally, roflumilast foam 0.3% (Zoryve) offers a steroid-free, easy-to-apply option for treating scalp and body psoriasis. Results from the ARRECTOR phase 3 trial highlight its potential to clear plaques and relieve symptoms in hair-bearing and other hard-to-treat areas.

We want to hear from you. Which of these PDUFA dates are you most excited about, and why? Cast your vote in our poll below and share your thoughts with the 

Dupilumab (Dupixent; Sanofi) for chronic spontaneous urticaria

Pz-cel (prademagenezamikeracel) (Abeona Therapeutics) for recessive dystrophic epidermolysis bullosa

Roflumilast foam 0.3% (Zoryve; Arcutis Biotherapeutics) for scalp and body psoriasis

Want to share more of your insights and perspectives with us? Email our team at 

Dupixent (dupilumab) sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (CSU). News release. Regeneron. November 15, 2024. Accessed January 3, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic

Abeona Therapeutics announces FDA accepts and grants Priority Review for pz-cel biologics license application (BLA). News release. Abeona Therapeutics. November 27, 2023. Accessed January 3, 2025. 

https://investors.abeonatherapeutics.com/press-releases/detail/268/abeona-therapeutics-announces-fda-accepts-and-grants

Arcutis submits supplemental new drug application for ZORYVE (roflumilast) foam to the FDA for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over. News release. Arcutis Biotherapeutics, Inc. July 23, 2024. Accessed January 3, 2025. 

https://www.arcutis.com/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-foam-to-the-fda-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over/

Significant advancements in dermatologic treatments are anticipated with three upcoming Prescription Drug User Fee Act (PDUFA) dates. Dupilumab (Dupixent) could become the first targeted therapy for chronic spontaneous urticaria in over a decade, offering hope for patients with uncontrolled symptoms. Prademagenezamikeracel (pz-cel) may revolutionize care for recessive dystrophic epidermolysis bullosa, addressing unmet needs in wound healing and pain management. Roflumilast foam 0.3% (Zoryve) provides a steroid-free option for treating scalp and body psoriasis, showing promise in clearing plaques and relieving symptoms.

Share your insights and anticipation with us.

POLL: Which Anticipated Drug Approval/PDUFA Date Are You Most Looking Forward to in 2025?

UCB announced today in a news release the introduction of a new single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of bimekizumab (Bimzelx). These newly available devices complement the existing 1 mL administration options, which each contain 160 mg of the medication. This development is expected to enhance the convenience of bimekizumab administration for patients requiring a 320 mg dose.

In the release, Camille Lee, head of US immunology at UCB, highlighted the significance of this advancement, stating, “With 5 new FDA-approved indications for [bimekizumab] in just over a year, we’ve had the opportunity to reach a wider range of people living with chronic inflammatory conditions who have long been in need of new treatment options. With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate to severe plaque psoriasis, active psoriatic arthritis (PsA) with coexistent moderate to severe plaque psoriasis, and moderate to severe hidradenitis suppurativa (HS) who receive a320 mg dose of [bimekizumab].”

The FDA approved the 320 mg single-injection option in October 2024. This approval followed data from clinical studies demonstrating the bioequivalence of bimekizumab 320 mg administered as a single 2 mL subcutaneous injection versus 2 1 mL subcutaneous injections.

 “Our goal with these single-injection regimens is to strengthen and expand administration options, increase convenience and enhance the individual patient experience,” Emmanuel Caeymaex, executive vice president, head of patient impact, chief commercial officer, UCB, said in the October 2024 release. “With the new device presentations, people with moderate to severe plaque psoriasis who receive a bimekizumab-bkzx maintenance dose of 320 mg will have the option of a single-injection every 8 weeks.”

The recommended indications for the 320 mg dose include:

Active PsA with coexistent moderate to severe plaque psoriasis

For other indications, including active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS), a 160 mg dose is recommended. The company stated bimekizumab’s broad range of indications and tailored dosing regimens provide treatment options for diverse patient needs. 

According to the release, bimekizumab is a humanized monoclonal IgG1 antibody designed to selectively inhibit interleukin 17A and interleukin 17F, cytokines that play a key role in inflammatory processes. By targeting these cytokines, the drug addresses chronic inflammation and tissue damage associated with conditions like plaque psoriasis, PsA, nr-axSpA, AS, and HS.

Bimekizumab is approved for the following indications:

 Treatment of moderate to severe plaque psoriasis in adults eligible for systemic therapy or phototherapy. Recommended dosage is 320 mg subcutaneously at weeks 0, 4, 8, 12, and 16, followed by maintenance doses every 8 weeks. For patients over 120 kg, consider a320 mg dose every 4 weeks after week 16.

Treatment of adults with active PsA. Recommended dosage is 160 mg subcutaneously every 4 weeks. For coexisting moderate to severe plaque psoriasis, follow the plaque psoriasis dosing regimen.

 Treatment of adults with active nr-axSpA with objective signs of inflammation. Recommended dosage is 160 mg subcutaneously every 4 weeks.

 Treatment of adults with active AS. Recommended dosage is 160 mg subcutaneously every 4 weeks.

Treatment of adults with moderate to severe HS. Recommended dosage is 320 mg subcutaneously at weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks. 

This new dosing option exemplifies UCB’s commitment to innovation and patient-centered care, addressing the evolving needs of individuals with chronic inflammatory diseases.

UCB announces US availability of 320 mg/2 mL single-injection administration option for BIMZELX® (bimekizumab-bkzx). News Release. PR Newswire. Published January 16, 2025. Accessed January 16, 2025. 

https://www.prnewswire.com/news-releases/ucb-announces-us-availability-of-320-mg2-ml-single-injection-administration-option-for-bimzelx-bimekizumab-bkzx-302352452.html

UCB receives US FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx). News Release. UCB. Published October 14, 2024. Accessed January 16, 2025. 

https://www.ucb.com/stories-media/Press-Releases/article/UCB-receives-US-FDA-approval-for-320-mg-single-injection-device-presentations-of-BIMZELXR-bimekizumab-bkzx

UCB has introduced a new 320 mg single-injection option for bimekizumab, enhancing convenience for patients with chronic inflammatory conditions. This development follows FDA approval, supported by clinical data demonstrating bioequivalence with the previous two-injection regimen. The new administration option is particularly beneficial for patients with moderate to severe plaque psoriasis, active psoriatic arthritis with coexistent plaque psoriasis, and moderate to severe hidradenitis suppurativa. Bimekizumab, a monoclonal antibody targeting interleukin 17A and 17F, offers tailored dosing regimens for various conditions, reflecting UCB's commitment to patient-centered care.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

UCB Launches 320mg Single-Injection Bimekizumab

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

 approximately 2% of people worldwide will experience hair loss due to alopecia areata in their lifetime. 

When taking this statistic into account, approximately 160 million people globally have had, currently have, or will have alopecia areata, including approximately 6.7 million in the US. 

At this moment in time, it can be approximated that 700,000 people in the US, both children and adults, currently have some form of alopecia areata.

Alopecia areata - National Alopecia Areata Foundation. NAAF. June 23, 2023. Accessed August 11, 2023. 

Alopecia areata affects approximately 2% of the global population, translating to around 160 million individuals worldwide. In the United States, about 6.7 million people have experienced or will experience this condition, with an estimated 700,000 currently affected. This autoimmune disorder impacts both children and adults, leading to varying degrees of hair loss. The data underscores the prevalence of alopecia areata and highlights the need for continued research and awareness to better understand and manage this condition.

This Hair Loss Awareness Month, test your knowledge of hair loss conditions. Click here to answer this week's poll.

Jason Luke, MD, FACP

Articles

Latest Updated Articles